EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants

Henry Fok, Mariko Harada-Shiba, David Rider, Yasuko Owada, Curtis Rambaran

Journal of Atherosclerosis and Thrombosis · 2026

DOI: 10.5551/jat.66214 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2026. Verfasst von Henry Fok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Silence Therapeutics. Hauptthemen laut MEDLINE: RNA, Small Interfering, Lipoprotein(a), Acetylgalactosamine, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Zerlasiran is an N-acetylgalactosamine-conjugated small interfering RNA that targets lipoprotein(a), a risk factor for atherosclerosis and calcific aortic stenosis. Zerlasiran has not been studied in Japanese participants previously. METHOD: This was an open-label, single-dose trial that enrolled 18 adult participants with lipoprotein(a) levels ≥ 70 nmol/L at a single site in Japan to evaluate subcutaneous doses of zerlasiran (30 mg, 100 mg, and 300 mg) in three ascending-dose cohorts. The participants were monitored for 150 days post-dose to assess the systemic pharmacokinetics, pharmacodynamics (lipoprotein (a) and lipid biomarkers), and safety. RESULTS: Following dosing, median Tmax was reached at 5 hours with plasma concentrations gradually declining to undetectable levels by 36 hours, with t1/2 approximately 4 hours. Both Cmax and AUC0-inf increased in a dose-dependent manner. The maximum median (interquartile range [IQR]) percent reduction in lipoprotein (a) in the 30 mg, 100 mg, and 300 mg cohorts were -72.8% (-79.7%, -67.1%), 88.8% (-89.5%, -84.7%), and -97.8% (-98.6, -96.9%), respectively, between days 30 and 60, with a sustained effect observed at 150 days at all dose levels. All adverse events were mild and self-limiting. CONCLUSION: Zerlasiran was well tolerated with no significant safety findings observed at any dose level. A typical pharmacokinetic profile expected of an N-acetylgalactosamine-conjugated small interfering RNA, coupled with a potent and sustained reduction in lipoprotein(a), was observed in Japanese participants. No adverse effects on either the liver or kidney function were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingLipoprotein(a)AcetylgalactosamineAtherosclerosisHumansFemaleMaleMiddle AgedJapanAdultAgedBiomarkersEast Asian People

Stichwörter der Autor:innen

Lipoprotein(a)PharmacokineticsSafetySmall interfering RNAZerlasiran

Substanzen

RNA, Small InterferingLipoprotein(a)AcetylgalactosamineBiomarkers

Autor:innen und Institutionen

  • Silence Therapeutics.
  • Cardiovascular Center, Osaka Medical and Pharmaceutical University.
  • Medical Corporation Heishinkai.

Zitieren

APA

Fok, H., Harada-Shiba, M., Rider, D., Owada, Y., & Rambaran, C. (2026). A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.66214

Vancouver

Fok H, Harada-Shiba M, Rider D, Owada Y, Rambaran C. A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants. Journal of Atherosclerosis and Thrombosis. 2026. doi:10.5551/jat.66214

BibTeX
@article{Fok2026,
  author = {Fok, Henry and Harada-Shiba, Mariko and Rider, David and Owada, Yasuko and Rambaran, Curtis},
  title = {A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2026},
  doi = {10.5551/jat.66214}
}
Kostenlos starten →